Superior Planning, LLC’s Amylyx Pharmaceuticals AMLX Stock Holding History

Superior Planning, LLC’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.4K	Buy	+565	New	+$15K	0.01%	761

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Superior Planning, LLC's AMLX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Amylyx Pharmaceuticals (AMLX) in Q3 2026: 565 shares worth $16.4K. The stake represents 0.01% of the portfolio and ranks #761 among its holdings.

111 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

Superior Planning, LLC held 565 shares of Amylyx Pharmaceuticals worth $16.4K as of Q3 2026.
Amylyx Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
Amylyx Pharmaceuticals made up 0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #761 holding.
111 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.